Stock News

As Diebold Nxdf (DBD) Share Price Declined, Holder Managed Asset Portfolios Has Trimmed Position by $5.16 Million; Gilead Sciences (GILD) Stake Boosted by Doheny Asset Management

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Managed Asset Portfolios Llc decreased its stake in Diebold Nxdf Inc (DBD) by 33.4% based on its latest 2018Q1 regulatory filing with the SEC. Managed Asset Portfolios Llc sold 143,279 shares as the company’s stock declined 23.05% with the market. The institutional investor held 285,696 shares of the miscellaneous company at the end of 2018Q1, valued at $10.50 million, down from 428,975 at the end of the previous reported quarter. Managed Asset Portfolios Llc who had been investing in Diebold Nxdf Inc for a number of months, seems to be less bullish one the $960.87 million market cap company. The stock decreased 1.17% or $0.15 during the last trading session, reaching $12.65. About 217,479 shares traded. Diebold Nixdorf, Incorporated (NYSE:DBD) has declined 55.78% since June 19, 2017 and is downtrending. It has underperformed by 68.35% the S&P500. Some Historical DBD News: 02/05/2018 – Diebold Nixdorf 1Q Rev $1.1B; 30/05/2018 – Diebold Non-Deal Roadshow Set By Northcoast Research for Jun. 6; 16/03/2018 – Diebold Closes Below 50-Day Moving Average: Technicals; 23/05/2018 – Diebold Nixdorf Appoints Ellen Costello to Bd of Directors; 11/05/2018 – GAMCO REPORTS 9.56% STAKE IN DIEBOLD INCORPORATED; 03/05/2018 – GAMCO REPORTS 8.56% STAKE IN DIEBOLD INCORPORATED; 25/04/2018 – Diebold Nixdorf Elects Board Members At Annual Shareholders Meeting; 11/04/2018 – Diebold Nixdorf Interactive Retail Kiosk Solution Receives Red Dot Design Award; 02/05/2018 – Diebold Nixdorf Sees 2018 Rev $4.5B-$4.7B; 29/05/2018 – Emirates NBD Introduces Integrated Digital Onboarding Service Enabled By Diebold Nixdorf

Doheny Asset Management increased its stake in Gilead Sciences Inc (GILD) by 47.39% based on its latest 2018Q1 regulatory filing with the SEC. Doheny Asset Management bought 11,255 shares as the company’s stock declined 17.62% with the market. The institutional investor held 35,006 shares of the health care company at the end of 2018Q1, valued at $2.64 million, up from 23,751 at the end of the previous reported quarter. Doheny Asset Management who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $91.17 billion market cap company. The stock increased 1.53% or $1.055 during the last trading session, reaching $70.115. About 1.99M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 19, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 19/04/2018 – DJ Gilead Sciences Inc, Inst Holders, 1Q 2018 (GILD); 30/05/2018 – GALAPAGOS – CO TO GET $15 MLN PAYMENT FROM GILEAD FOR PROGRESSION INTO PHASE 3 OF PHASE 2B/3 SELECTION STUDY OF FILGOTINIB IN ULCERATIVE COLITIS; 30/05/2018 – GALAPAGOS NV – FILGOTINIB WAS GENERALLY WELL-TOLERATED IN EQUATOR TRIAL, WITH NO NEW SAFETY SIGNALS OBSERVED; 17/05/2018 – GILEAD, CELGENE, NOVARTIS NAMED MULTIPLE TIMES IN FDA LIST; 15/05/2018 – Gilead Sciences: U.S. FDA Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 in Adolescents; 10/04/2018 – FOCUS-Lonza’s virus factory shows gene therapy’s Texas-sized promise; 12/04/2018 – STAT Plus: Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?; 30/05/2018 – GALAPAGOS NV – EQUATOR ACHIEVES PRIMARY ENDPOINT OF ACR20 RESPONSE AT WEEK 16; 05/03/2018 – GLAXOSMITHKLINE UNIT: DOLUTEGRAVIR MET INSPIRING STUDY ENDPOINT; 17/04/2018 – GE rides gene therapy wave with ready-made viral drug factories

Investors sentiment increased to 0.88 in 2018 Q1. Its up 0.08, from 0.8 in 2017Q4. It increased, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Northeast Inv reported 4,620 shares. Barry Advisors Ltd Llc reported 10,952 shares stake. Synovus Corp invested 0.13% in Gilead Sciences, Inc. (NASDAQ:GILD). Moreover, Kistler has 0.28% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Castleark Mgmt Limited Liability Corp has 107,748 shares. Martin Investment Limited Liability Co invested 3.08% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). South State Corp holds 7,722 shares or 0.07% of its portfolio. Captrust Finance Advsrs has invested 0.04% in Gilead Sciences, Inc. (NASDAQ:GILD). Rhenman And Prtnrs Asset Management reported 237,027 shares. Amundi Pioneer Asset Mgmt invested 1.03% in Gilead Sciences, Inc. (NASDAQ:GILD). Retail Bank Of America Corp De holds 7.83 million shares. Gsa Capital Prtn Ltd Liability Partnership holds 0.2% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 49,441 shares. Woodley Farra Manion Portfolio Mngmt reported 358,413 shares. Needham Invest Mgmt Lc has invested 3.38% in Gilead Sciences, Inc. (NASDAQ:GILD). Shelton Capital Mngmt owns 180,175 shares or 0.89% of their US portfolio.

Since January 2, 2018, it had 0 buys, and 23 selling transactions for $48.21 million activity. $430,130 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Cogan John Francis. Another trade for 50,000 shares valued at $3.41M was sold by MARTIN JOHN C. 100,000 shares valued at $8.02 million were sold by Meyers James R on Tuesday, January 16. WILSON GAYLE E had sold 60,000 shares worth $4.68M on Friday, February 9. 5,000 Gilead Sciences, Inc. (NASDAQ:GILD) shares with value of $401,566 were sold by Washington Robin L.

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Nasdaq.com which released: “5 Top Stocks to Buy in June” on June 01, 2018, also Seekingalpha.com with their article: “Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 39th Annual Global Healthcare Conference (Transcript)” published on June 13, 2018, Seekingalpha.com published: “Gilead’s Evolution In Oncology, With Comments On Valuation” on June 07, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead: Novartis’s Kymriah Is Coming To America” published on May 24, 2018 as well as Seekingalpha.com‘s news article titled: “Gilead: Growth Pick For Your Portfolio” with publication date: June 15, 2018.

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. On Wednesday, February 7 the stock rating was maintained by Cowen & Co with “Buy”. The rating was maintained by Wells Fargo with “Buy” on Monday, January 29. The firm has “Overweight” rating given on Wednesday, May 2 by Barclays Capital. Leerink Swann maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Thursday, October 5. Leerink Swann has “Market Perform” rating and $89 target. The company was maintained on Thursday, February 22 by Leerink Swann. Vetr upgraded it to “Buy” rating and $129.16 target in Monday, August 17 report. The company was maintained on Friday, September 15 by Robert W. Baird. The rating was maintained by Mizuho on Monday, February 5 with “Buy”. On Wednesday, February 3 the stock rating was maintained by Piper Jaffray with “Overweight”. On Tuesday, May 30 the stock rating was maintained by Maxim Group with “Hold”.

Doheny Asset Management, which manages about $245.55M and $190.49M US Long portfolio, decreased its stake in Wells Fargo Bk N A (NYSE:WFC) by 61,927 shares to 11,960 shares, valued at $627,000 in 2018Q1, according to the filing. It also reduced its holding in Alphabet Inc. Class A by 590 shares in the quarter, leaving it with 3,616 shares, and cut its stake in Northrop Grumman Corp (NYSE:NOC).

Since February 28, 2018, it had 5 buys, and 0 selling transactions for $596,037 activity. ALLENDER PATRICK W bought 25,000 shares worth $296,683. Another trade for 3,000 shares valued at $34,764 was bought by FITZGERALD GALE S. 3,000 shares valued at $48,150 were bought by Chapman Christopher A. on Wednesday, February 28.

Managed Asset Portfolios Llc, which manages about $361.80 million and $311.00M US Long portfolio, upped its stake in Seaworld Entmt Inc (NYSE:SEAS) by 74,293 shares to 458,733 shares, valued at $6.80M in 2018Q1, according to the filing. It also increased its holding in Vodafone Group Plc New (NASDAQ:VOD) by 18,394 shares in the quarter, for a total of 650,928 shares, and has risen its stake in Bunge Limited (NYSE:BG).

Analysts await Diebold Nixdorf, Incorporated (NYSE:DBD) to report earnings on July, 18. They expect $0.01 EPS, down 87.50% or $0.07 from last year’s $0.08 per share. DBD’s profit will be $759,580 for 316.25 P/E if the $0.01 EPS becomes a reality. After $-0.12 actual EPS reported by Diebold Nixdorf, Incorporated for the previous quarter, Wall Street now forecasts -108.33% EPS growth.

More recent Diebold Nixdorf, Incorporated (NYSE:DBD) news were published by: Seekingalpha.com which released: “Tracking Alex Roepers’ Atlantic Investment Management Portfolio – Q1 2018 Update” on May 24, 2018. Also Prnewswire.com published the news titled: “Diebold Nixdorf Appoints Ellen Costello To Board Of Directors” on May 23, 2018. Seekingalpha.com‘s news article titled: “Diebold Nixdorf: Opportunity Or Death Spiral?” with publication date: June 14, 2018 was also an interesting one.

Among 10 analysts covering Diebold Inc (NYSE:DBD), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Diebold Inc had 32 analyst reports since July 29, 2015 according to SRatingsIntel. As per Wednesday, February 14, the company rating was maintained by Credit Suisse. As per Wednesday, September 16, the company rating was maintained by Imperial Capital. The firm has “Buy” rating given on Tuesday, August 25 by TheStreet. JP Morgan upgraded Diebold Nixdorf, Incorporated (NYSE:DBD) on Thursday, November 16 to “Overweight” rating. The stock has “In-Line” rating by Imperial Capital on Tuesday, May 3. The stock has “Outperform” rating by Wedbush on Friday, July 31. The stock of Diebold Nixdorf, Incorporated (NYSE:DBD) has “Hold” rating given on Tuesday, October 31 by Lake Street. The company was downgraded on Tuesday, August 8 by JP Morgan. KeyBanc Capital Markets maintained Diebold Nixdorf, Incorporated (NYSE:DBD) on Wednesday, August 23 with “Hold” rating. The firm has “Neutral” rating given on Wednesday, November 1 by JP Morgan.

Investors sentiment increased to 1.35 in Q1 2018. Its up 0.24, from 1.11 in 2017Q4. It improved, as 14 investors sold DBD shares while 58 reduced holdings. 22 funds opened positions while 75 raised stakes. 80.28 million shares or 0.53% less from 80.71 million shares in 2017Q4 were reported. Glenmede Trust Na has invested 0% of its portfolio in Diebold Nixdorf, Incorporated (NYSE:DBD). Ubs Asset Mgmt Americas has 64,626 shares for 0% of their portfolio. Advantus Cap Incorporated reported 0% stake. Park National Corporation Oh holds 0.01% or 13,283 shares. Fifth Third Bank & Trust has invested 0% in Diebold Nixdorf, Incorporated (NYSE:DBD). Gamco Invsts Et Al reported 3.99M shares. Gotham Asset Mngmt Ltd Liability Company has 0.1% invested in Diebold Nixdorf, Incorporated (NYSE:DBD) for 460,386 shares. 51,368 are held by Arizona State Retirement System. Neuberger Berman Gru Limited Liability reported 1.72 million shares stake. Teton Advsrs Inc owns 105,564 shares. Lpl Fincl reported 56,265 shares. Oppenheimer & Company Inc stated it has 38,324 shares or 0.02% of all its holdings. Alliancebernstein Lp reported 127,145 shares. Quantitative Inv Management Ltd Liability holds 68,200 shares. Goldman Sachs Group invested in 0% or 440,915 shares.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *